Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Progenity, Inc.    PROG

PROGENITY, INC.

(PROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
4(c) 3.92(c) 3.64(c) 3.9(c) 3.91(c) Last
158 436 267 632 438 654 452 349 293 186 Volume
-3.85% -2.00% -7.14% +7.14% +0.26% Change
More quotes
Financials (USD)
Sales 2020 86,6 M - -
Net income 2020 -159 M - -
Net cash position 2020 10,6 M - -
P/E ratio 2020 -0,66x
Yield 2020 -
Sales 2021 144 M - -
Net income 2021 -183 M - -
Net Debt 2021 14,3 M - -
P/E ratio 2021 -1,14x
Yield 2021 -
Capitalization 184 M 184 M -
EV / Sales 2020 2,00x
EV / Sales 2021 1,38x
Nbr of Employees 702
Free-Float 64,0%
More Financials
Company
Progenity, Inc. is a biotechnology company. The Company is engaged in developing and commercializing molecular testing products and precision medicine. It applies multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise... 
More about the company
All news about PROGENITY, INC.
11/20PROGENITY, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/20NEW TEST FOR TRIAGING PREECLAMPSIA P : Progenity Releases Prospective Clinical V..
AQ
11/20NEW TEST FOR TRIAGING PREECLAMPSIA P : Progenity Releases Prospective Clinical V..
GL
11/18PROGENITY, INC. : Costs Associated with Exit or Disposal Activities, Other Event..
AQ
11/17PROGENITY : to Present at 2020 San Antonio Breast Cancer Virtual Symposium
AQ
11/17Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium
GL
11/16PROGENITY : to Participate in the 32nd Annual Piper Sandler Healthcare Conferenc..
AQ
11/16Progenity to Participate in the 32nd Annual Piper Sandler Healthcare Conferen..
GL
11/13Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020
GL
11/13PROGENITY : to Host Preeclampsia Virtual R&D Day on November 20, 2020
AQ
11/09PROGENITY : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/09PROGENITY, INC. : Results of Operations and Financial Condition, Financial State..
AQ
11/09PROGENITY : Provides Corporate Updates and Reports Third Quarter 2020 Financial ..
AQ
11/09Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial..
GL
11/06PROGENITY : Announces Encouraging Preclinical Data Supporting the Potential of t..
AQ
More news
News in other languages on PROGENITY, INC.

- No features available -

More news
Chart PROGENITY, INC.
Duration : Period :
Progenity, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROGENITY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 11,60 $
Last Close Price 3,91 $
Spread / Highest target 284%
Spread / Average Target 197%
Spread / Lowest Target 156%
EPS Revisions
Managers
NameTitle
Harry Stylli Chairman & Chief Executive Officer
Damon Silvestry Chief Operating Officer
Eric d'Esparbes Chief Financial Officer
Matthew Cooper Chief Scientific Officer
Troy Seelye Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROGENITY, INC.0.00%184
SARTORIUS AG86.86%27 788
REVENIO GROUP OYJ54.67%1 283
ALPHATEC HOLDINGS, INC.54.33%859
CELLAVISION AB (PUBL)-13.68%772
VAREX IMAGING CORPORATION-44.01%652